LOCIURO, LAURA
LOCIURO, LAURA
Dipartimento di Biotecnologie Mediche e Medicina Traslazionale
Combination therapy targeting HDAC8 and SIRT1 improves muscle integrity in a dmd zebrafish model
2026 S. Carbone, A. Brix, L. Lociuro, M. Schiavone, O. Gjana, L. Belleri, A. Marozzi, F. Del Bene, C. De Palma, A. Pistocchi, A. Pezzotta
Combination therapy targeting HDAC8 and SIRT1 improves muscle integrity in a dmd zebrafish model
2025 S. Carbone, A. Brix, L. Lociuro, O. Gjana, L. Belleri, M. Schiavone, A. Marozzi, F. Del Bene, C. De Palma, A. Pezzotta, A. Pistocchi
Therapeutic potential of HDAC8 Inhibition and SIRT1 activation in Duchenne muscular dystrophy
2025 S. Carbone, A. Brix, L. Lociuro, O. Gjana, L. Belleri, M. Schiavone, A. Marozzi, F. Del Bene, C. De Palma, A. Pistocchi, A. Pezzotta
Therapeutic potential of HDAC8 Inhibition and SIRT1 activation in Duchenne muscular dystrophy
2025 S. Carbone, A. Brix, L. Lociuro, O. Gjana, L. Belleri, M. Schiavone, A. Marozzi, F. Del Bene, C. De Palma, A. Pistocchi, A. Pezzotta
The SIRT1 activator SRT2104 exerts exercise mimetic effects and promotes Duchenne muscular dystrophy recovery
2025 M. Giovarelli, S. Zecchini, S.R. Casati, L. Lociuro, O. Gjana, L. Mollica, E. Pisanu, H.D. Mbissam, O. Cappellari, C. De Santis, A. Arcari, A. Bigot, G. Clerici, E. Catalani, S. Del Quondam, A. Andolfo, C. Braccia, M.G. Cattaneo, C. Banfi, D. Brunetti, E. Mocciaro, A. De Luca, E. Clementi, D. Cervia, C. Perrotta, C. De Palma
Enhancing micro-dystrophin gene therapy: the role of SRT2104, a new Sirtuin1-activating compound, for the treatment of Duchenne Muscular Dystrophy
2024 L. Lociuro, S.R. Casati, O. Gjana, S. Zecchini, M. Giovarelli, C. Perrotta, C. De Palma
SRT2104, a new SIRT1 activator, is an effective metabolic enhancer that promotes muscle recovery in DMD
2024 L. Lociuro, O. Gjana, S.R. Casati, S. Zecchini, M. Giovarelli, D. Brunetti, G. Clerici, M.G. Cattaneo, C. Banfi, L. Mollica, C. De Palma
Enhancing micro-dystrophin gene therapy: the role of SRT2104, a new Sirtuin1-activating compound, for the treatment of Duchenne Muscular Dystrophy
2024 L. Lociuro, S.R. Casati, O. Gjana, S. Zecchini, M. Giovarelli, C. Perrotta, C. De Palma
Enhancing micro-dystrophin gene therapy: the role of SRT2104, a new Sirtuin1-activating compound, for the treatment of Duchenne Muscular Dystrophy
2024 L. Lociuro, S.R. Casati, O. Gjana, S. Zecchini, M. Giovarelli, C. Perrotta, C. De Palma
Oral administration of plumbagin is beneficial in in vivo models of Duchenne muscular dystrophy through control of redox signaling
2024 D. Cervia, S. Zecchini, L. Pincigher, P. Roux-Biejat, C. Zalambani, E. Catalani, A. Arcari, S. Del Quondam, K. Brunetti, R. Ottria, S. Casati, C. Vanetti, M.C. Barbalace, C. Prata, M. Malaguti, S.R. Casati, L. Lociuro, M. Giovarelli, E. Mocciaro, S. Falcone, C. Fenizia, C. Moscheni, S. Hrelia, C. De Palma, E. Clementi, C. Perrotta
Improving the effects of HDAC8 inhibition by combining the activation of SIRT1 in a zebrafish model of Duchenne muscular dystrophy
2024 A. Pezzotta, S. Carbone, M. Cafora, A. Brix, L. Belleri, M. Giovarelli, L. Lociuro, M. Schiavone, A. Marozzi, F. Del Bene, C. De Palma, A. Pistocchi